Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objective was to compare the efficacy of once daily subcutaneous injections of
Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism [VTE]
in cancer patients at high risk for VTE and who were undergoing chemotherapy.
The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to
document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of
VTE and to assess the survival status at one year in this population.